Effectiveness and safety of salmeterol in nonspecialist practice settings.
about
Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adultsIntermittent versus daily inhaled corticosteroids for persistent asthma in children and adultsAddition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenAddition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenRegular treatment with salmeterol for chronic asthma: serious adverse eventsAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adultsLong-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidTolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review.Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis.Safety of long-acting beta2-agonists in the management of asthma: a Primary Care Respiratory Alliance of Canada perspective.
P2860
Q24200804-8E642FF2-533E-47F6-81FA-59B63DEED3D7Q24202489-169E5682-5F19-4DFF-B18C-C06EAB256561Q24235303-6C118825-3149-469B-84B7-DFB0E02656D1Q24235964-3C8989A7-1F3E-4481-A848-E519447D2A92Q24240464-4D166A8D-D0B3-44E3-BBD6-104A10808F73Q24241960-E2D751EB-7284-47FE-BE03-2C9B2EE7BA12Q24245719-DB2C59B2-1B82-4D31-8257-C51C937A08CAQ24246441-86769C35-2E70-4233-A0C7-BBE91253949BQ36892408-4F7E458D-F5F2-424A-BBAA-4CF148CA265EQ37362634-259EA404-7E2F-4D5E-8C4B-F03059D44A2AQ37522916-1CA98B94-8CC0-4B0F-B583-CA876435A6E2Q38219526-F7A14219-B69C-4B78-85AF-1873D10D257DQ42917507-EFE5626C-9FB2-4048-B531-12DF372443C1
P2860
Effectiveness and safety of salmeterol in nonspecialist practice settings.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effectiveness and safety of salmeterol in nonspecialist practice settings.
@ast
Effectiveness and safety of salmeterol in nonspecialist practice settings.
@en
type
label
Effectiveness and safety of salmeterol in nonspecialist practice settings.
@ast
Effectiveness and safety of salmeterol in nonspecialist practice settings.
@en
prefLabel
Effectiveness and safety of salmeterol in nonspecialist practice settings.
@ast
Effectiveness and safety of salmeterol in nonspecialist practice settings.
@en
P2093
P356
P1433
P1476
Effectiveness and safety of salmeterol in nonspecialist practice settings.
@en
P2093
Chapman KR
Fitzgerald M
Hargreave FE
Tesarowski D
P304
P356
10.1378/CHEST.119.3.714
P407
P577
2001-03-01T00:00:00Z